Literature DB >> 31381510

Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.

Katie E Osborn1, Jonathan M Alverio2, Logan Dumitrescu1, Kimberly R Pechman1, Katherine A Gifford1, Timothy J Hohman1,3, Kaj Blennow4,5, Henrik Zetterberg4,5,6,7, Angela L Jefferson1.   

Abstract

BACKGROUND: Vascular risk factors promote cerebral small vessel disease and neuropathological changes, particularly in white matter where large-caliber axons are located. How Alzheimer's disease pathology influences the brain's vulnerability in this regard is not well understood.
OBJECTIVE: Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions by clinical and protein markers of Alzheimer's disease.
METHODS: Among Alzheimer's Disease Neuroimaging Initiative participants with normal cognition (n = 117), mild cognitive impairment (n = 190), and Alzheimer's disease (n = 95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis. Interactions were assessed by cognitive diagnosis, and by cerebrospinal fluid markers of Aβ42, hyperphosphorylated tau, and total tau.
RESULTS: Vascular risk and neurofilament light were not related in the main effect model (p = 0.08). However, interactions emerged for total tau (p = 0.01) and hyperphosphorylated tau (p = 0.002) reflecting vascular risk becoming more associated with cerebrospinal fluid neurofilament light in the context of greater concentrations of tau biomarkers. An interaction also emerged for the Alzheimer's disease biomarker profiles (p = 0.046) where in comparison to the referent 'normal' biomarker group, individuals with abnormal levels of both Aβ42 and total tau showed stronger associations between vascular risk and neurofilament light.
CONCLUSION: Older adults may be more vulnerable to axonal injury in response to higher vascular risk burdens in the context of concomitant Alzheimer's disease pathology.

Entities:  

Keywords:  Alzheimer’s disease; cerebrovascular; neurodegeneration; neurofilament zzm321990light; vascular risk

Year:  2019        PMID: 31381510      PMCID: PMC6877290          DOI: 10.3233/JAD-190077

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  57 in total

Review 1.  Clinical diagnosis of prolonged states of impaired consciousness in adults.

Authors:  Eelco F M Wijdicks; Ronald E Cranford
Journal:  Mayo Clin Proc       Date:  2005-08       Impact factor: 7.616

2.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.

Authors:  D A Snowdon; L H Greiner; J A Mortimer; K P Riley; P A Greiner; W R Markesbery
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

3.  Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions.

Authors:  Sylvia Villeneuve; Bruce R Reed; Cindee M Madison; Miranka Wirth; Natalie L Marchant; Stephen Kriger; Wendy J Mack; Nerses Sanossian; Charles DeCarli; Helena C Chui; Michael W Weiner; William J Jagust
Journal:  Neurology       Date:  2014-06-06       Impact factor: 9.910

4.  Differentiated cerebrovascular effects of physostigmine and tacrine in cortical areas deafferented from the nucleus basalis magnocellularis suggest involvement of basalocortical projections to microvessels.

Authors:  P Peruzzi; D von Euw; P Lacombe
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

5.  The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemia-reperfusion brain injury. A model of early Alzheimer's disease.

Authors:  R Pluta
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

6.  Adverse vascular risk is related to cognitive decline in older adults.

Authors:  Angela L Jefferson; Timothy J Hohman; Dandan Liu; Shereen Haj-Hassan; Katherine A Gifford; Elleena M Benson; Jeannine S Skinner; Zengqi Lu; Jamie Sparling; Emily C Sumner; Susan Bell; Frederick L Ruberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 7.  Chronic disorders of consciousness.

Authors:  James L Bernat
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

8.  Late and early onset dementia: what is the role of vascular factors? A retrospective study.

Authors:  Anna Carotenuto; Raffaele Rea; Luisa Colucci; Antonio Rosario Ziello; Ivana Molino; Sabrina Carpi; Enea Traini; Francesco Amenta; Angiola Maria Fasanaro
Journal:  J Neurol Sci       Date:  2012-09-09       Impact factor: 3.181

9.  Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study.

Authors:  Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

10.  Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

Authors:  Ching-Hua Lu; Corrie Macdonald-Wallis; Elizabeth Gray; Neil Pearce; Axel Petzold; Niklas Norgren; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Kevin Talbot; Linda Greensmith; Jens Kuhle; Martin R Turner; Andrea Malaspina
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

View more
  4 in total

1.  White Matter Disease and Outcomes of Mechanical Thrombectomy for Acute Ischemic Stroke.

Authors:  E A Mistry; A M Mistry; T Mehta; N Arora; A K Starosciak; F D L R La Rosa; J E Siegler; S E Kasner; R Chitale; M Fusco; M Froehler; S Yaghi; M Schrag; P Khatri
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

2.  Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.

Authors:  Katherine J Bangen; Kelsey R Thomas; Alexandra J Weigand; Emily C Edmonds; Alexandra L Clark; Seraphina Solders; Lisa Delano-Wood; Douglas R Galasko; Mark W Bondi
Journal:  Alzheimers Dement       Date:  2021-04-15       Impact factor: 16.655

3.  White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

Authors:  Linda J C van Waalwijk van Doorn; Mohsen Ghafoorian; Esther M C van Leijsen; Jurgen A H R Claassen; Andrea Arighi; Marco Bozzali; Jorge Cannas; Enrica Cavedo; Paolo Eusebi; Lucia Farotti; Chiara Fenoglio; Juan Fortea; Giovanni B Frisoni; Daniela Galimberti; Viviana Greco; Sanna-Kaisa Herukka; Yawu Liu; Alberto Lleó; Alexandre de Mendonça; Flavio M Nobili; Lucilla Parnetti; Agnese Picco; Maria Pikkarainen; Nicola Salvadori; Elio Scarpini; Hilkka Soininen; Roberto Tarducci; Andrea Urbani; Eduard Vilaplana; Olga Meulenbroek; Bram Platel; Marcel M Verbeek; H Bea Kuiperij
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

4.  Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.

Authors:  Xincui Fang; Jing Zhang; Jianping Zhao; Litao Wang
Journal:  J Healthc Eng       Date:  2022-03-25       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.